Effect of Intravenous Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation (EFFECT-KTx): rationale and study protocol for a double-blind, randomised, placebo-controlled trial
| Autor: | Arjan D van Zuilen, Stefan P Berger, Wayel H Abdulahad, Michele F Eisenga, Jacoba M Spikman, Martin H de Borst, P van der Meer, Carlo A J M Gaillard, Stephan JL Bakker, Joanna SJ Vinke, Jan-Stephan F Sanders |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | BMJ Open, Vol 13, Iss 3 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2044-6055 07748647 |
| DOI: | 10.1136/bmjopen-2022-065423 |
| Popis: | Introduction Iron deficiency (ID) is common and has been associated with an excess mortality risk in kidney transplant recipients (KTRs). In patients with chronic heart failure and ID, intravenous iron improves exercise capacity and quality of life. Whether these beneficial effects also occur in KTRs is unknown. The main objective of this trial is to address whether intravenous iron improves exercise tolerance in iron-deficient KTRs.Methods and analysis The Effect of Ferric Carboxymaltose on Exercise Capacity after Kidney Transplantation study is a multicentre, double-blind, randomised, placebo-controlled clinical trial that will include 158 iron-deficient KTRs. ID is defined as plasma ferritin |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|